Literature DB >> 1898256

Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease.

B T Henderson1, C G Clough, R C Hughes, E R Hitchcock, B G Kenny.   

Abstract

Disaggregated ventral mesencephalic tissue from single aborted human fetuses of 11 to 18 weeks' gestation was implanted stereotaxically into a consistent striatal site in 12 patients with advanced Parkinson's disease. All were receiving optimum levodopa therapy and were examined preoperatively and at 3,6,9, and 12 months postoperatively. Immunosuppression was not used. There were significant sustained improvements at 12 months in three patients; motor fluctuations were absent in two. There were modest group improvements up to 6 months, with increased quality of "on" and "off" phases, quantity of on times, and specific improvements in contralateral upper limb bradykinesia. Preoperative levodopa requirements were reduced to a mean of 64% at 6 months and 61% at 12 months. Deterioration below baseline ratings occurred in three of nine patients who had consistent follow-up to 12 months. Grafting of midgestational human fetal tissue can lead to improvement in Parkinson's disease. Individual disease severity may be critical, and further trials are needed to identify host factors influencing outcome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898256     DOI: 10.1001/archneur.1991.00530200062020

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

2.  Establishment and characterization of immortalized clonal cell lines from fetal rat mesencephalic tissue.

Authors:  K N Prasad; E Carvalho; S Kentroti; J Edwards-Prasad; C Freed; A Vernadakis
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-09       Impact factor: 2.416

3.  New aspects of neurotransplantation.

Authors:  S Woerly; D J Morassutti
Journal:  Neurosurg Rev       Date:  1993       Impact factor: 3.042

4.  Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. Network of European CNS Transplantation and Restoration (NECTAR).

Authors:  G J Boer
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

5.  Future of cell and gene therapies for Parkinson's disease.

Authors:  Ole Isacson; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

6.  A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions.

Authors:  L E Annett; E M Torres; R M Ridley; H F Baker; S B Dunnett
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

Review 7.  Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?

Authors:  Jia-Yi Li; Wen Li
Journal:  Front Cell Dev Biol       Date:  2021-05-13

Review 8.  Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results.

Authors:  E D Clarkson
Journal:  Drugs Aging       Date:  2001       Impact factor: 4.271

9.  Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease.

Authors:  Su-Ping Peng; Sjef Copray
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

10.  The Effect of Sertoli Cells on Xenotransplantation and Allotransplantation of Ventral Mesencephalic Tissue in a Rat Model of Parkinson's Disease.

Authors:  Yun-Ting Jhao; Chuang-Hsin Chiu; Chien-Fu F Chen; Ta-Kai Chou; Yi-Wen Lin; Yu-Ten Ju; Shinn-Chih Wu; Ruoh-Fang Yan; Chyng-Yann Shiue; Sheau-Huei Chueh; Christer Halldin; Cheng-Yi Cheng; Kuo-Hsing Ma
Journal:  Cells       Date:  2019-11-11       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.